Clovis Oncology (NDAQ:CLVS) Received New Janney Montgomery Scott Rating, Quantenna Communications (QTNA) Shorts Lowered By 6.12%

June 20, 2017 - By Marguerite Chambers

Quantenna Communications Incorporated (NASDAQ:QTNA) had a decrease of 6.12% in short interest. QTNA’s SI was 1.00M shares in June as released by FINRA. Its down 6.12% from 1.07M shares previously. With 467,900 avg volume, 2 days are for Quantenna Communications Incorporated (NASDAQ:QTNA)’s short sellers to cover QTNA’s short positions. The SI to Quantenna Communications Incorporated’s float is 7.03%. About 433,763 shares traded. Quantenna Communications Inc (NASDAQ:QTNA) has 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 2 analysts covering Clovis Oncology Inc (NDAQ:CLVS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Clovis Oncology Inc has $74 highest and $50 lowest target. $62’s average target is -30.16% below currents $88.78 stock price. Clovis Oncology Inc had 3 analyst reports since April 19, 2017 according to SRatingsIntel. The rating was maintained by Credit Suisse on Wednesday, April 19 with “Outperform”. The firm earned “Neutral” rating on Monday, June 19 by Chardan Capital Markets. Credit Suisse maintained Clovis Oncology Inc (NASDAQ:CLVS) on Friday, June 16 with “Outperform” rating.

Among 3 analysts covering Quantenna Communications (NASDAQ:QTNA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quantenna Communications had 3 analyst reports since November 22, 2016 according to SRatingsIntel. Deutsche Bank initiated the stock with “Buy” rating in Tuesday, November 22 report. Needham upgraded the stock to “Strong Buy” rating in Monday, December 5 report. As per Tuesday, November 22, the company rating was initiated by Barclays Capital.

Quantenna Communications, Inc. is engaged in the design, development and marketing of wireless communication solutions enabling wireless local area networking. The company has market cap of $736.25 million. The Company’s solutions are designed to deliver wireless fidelity performance to support various connected devices accessing a pool of digital content. It currently has negative earnings. The Firm combines its wireless systems and software expertise with radio frequency, mixed-signal and digital semiconductor design skills to provide solutions to its customers.

Investors sentiment decreased to 1.03 in 2016 Q4. Its down 0.97, from 2 in 2016Q3. It turned negative, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. 35.69 million shares or 2.51% less from 36.61 million shares in 2016Q3 were reported. 1,917 were reported by Fifth Third Financial Bank. Healthcor Management Lp has invested 1.57% in Clovis Oncology Inc (NASDAQ:CLVS). Finemark Fincl Bank & Tru owns 13 shares for 0% of their portfolio. Raymond James & Associates has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Bancorporation Of Montreal Can owns 12,502 shares. Jefferies Grp Lc invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Partner Inv Mgmt L P invested 1.51% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Voloridge Invest Mgmt Ltd Co stated it has 183,693 shares. California-based Partner Fund Mgmt Limited Partnership has invested 1.6% in Clovis Oncology Inc (NASDAQ:CLVS). Alliancebernstein Ltd Partnership holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 46,040 shares. Great West Life Assurance Can has 2,793 shares. Clough Prtn Lp, Massachusetts-based fund reported 15,800 shares. Sg Americas Limited Company invested 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Moreover, Metropolitan Life Ins Ny has 0.01% invested in Clovis Oncology Inc (NASDAQ:CLVS). Putnam Invests Ltd Llc, Massachusetts-based fund reported 43,185 shares.

About 5.00 million shares traded or 156.41% up from the average. Clovis Oncology Inc (NDAQ:CLVS) has risen 282.71% since June 20, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.

Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on August, 14. They expect $-1.37 earnings per share, up 33.82% or $0.70 from last year’s $-2.07 per share. After $-1.33 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts 3.01% negative EPS growth.